SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Travere Therapeutics, Inc.

SG&A Efficiency: A Tale of Two Companies

In the world of corporate finance, Selling, General, and Administrative (SG&A) expenses are a critical measure of operational efficiency. This analysis compares the SG&A expenses of Walgreens Boots Alliance, Inc. and Travere Therapeutics, Inc. over a decade, from 2014 to 2023.

Walgreens Boots Alliance, Inc.

Walgreens Boots Alliance, a retail pharmacy giant, consistently reported high SG&A expenses, peaking at approximately $28.1 billion in 2024. This reflects its expansive global operations and extensive retail network. Over the years, Walgreens' SG&A expenses have shown a steady increase, highlighting its investment in growth and operational scale.

Travere Therapeutics, Inc.

In contrast, Travere Therapeutics, a biopharmaceutical company, exhibited a more modest SG&A expense profile, starting at around $59.6 million in 2014 and rising to $265.5 million by 2023. This growth, over 340%, underscores Travere's strategic expansion and increased market presence.

The data reveals a stark contrast in scale and strategy between these two companies, offering valuable insights into their operational priorities.